Title:Strategies for Targeting CIB1: A Challenging Drug Target
Volume: 28
Issue: 28
Author(s): Muhammad Shahab, Abdul Wadood*Guojun Zheng*
Affiliation:
- Department of Biochemistry, Computational Medicinal Chemistry Laboratory, UCSS, Abdul Wali Khan University, Mardan,
Pakistan
- State Key Laboratories of Chemical Resources Engineering Beijing University of Chemical Technology, Beijing 100029, China
Keywords:
CIB1 protein, breast cancer, TNBC, HER2, progesterone receptor, estrogen receptor.
Abstract: Breast cancer is a common malignancy in women and is a diverse disease. In women, 287,850 and in
males 2710 cases are reported in 2022 by WHO. Triple-negative breast cancer (TNBC), a subtype of breast
cancer that lacks expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal
growth factor receptor 2 (HER2), accounted for 10-20% of all new cases discovered in the United States in
2017. Because calcium integrin-binding protein1 lacks a suitable pocket that could be used to create a chemical
inhibitor, and because the breast cancer-causing protein is nearly identical to its necessary wild-type counterpart,
it was thought to be druggable. The structure and function of the newly discovered calcium integrinbinding
protein1 have been improved, paving the way for the designing of several therapeutic candidates. Currently,
no FDA-approved drugs are available for CIB1-driven cancer. CIB1 has proven to challenge drug target
due to several factors, including the fact that the CIB1 protein is highly resistant to small inhibitors. This study
aimed to present various ways for targeting calcium integrin-binding protein1, which is an important target that
could be useful to scientists.
